Overview of Tivicay

Tivicay: Quick Overview and Key Facts

Property	Description
Active Ingredient	Dolutegravir (DTG)
Form	Film-coated Tablets (Oral administration)
Pharmacological Class	Integrase Inhibitor (INSTI)
Origin	Synthetic Compound
General Purpose	To achieve and maintain viral suppression

What Type of Medicine is Tivicay?

Tivicay is a brand-name prescription medication containing the active ingredient dolutegravir, which is a synthetic compound. Its primary classification is as an antiretroviral agent.

This medication belongs to a class known as Integrase Strand Transfer Inhibitors (INSTIs). This drug class is characterized by its pharmacological mechanism and its role in modern treatment strategies. Dolutegravir is recognized for having a high genetic barrier to resistance, a characteristic that supports its use in long-term therapeutic management. As an Integrase Inhibitor, it functions differently than older classes of antiretrovirals and is a frequent component in initial treatment regimens.

Composition and Physical Form of Dolutegravir

The therapeutic function of Tivicay is derived from the synthetic compound dolutegravir, which is the sole active ingredient in the formulation.

Dolutegravir is prepared for oral administration and is supplied in the form of film-coated tablets. While Tivicay itself is a single-ingredient product, the active ingredient is also utilized in various fixed-dose combinations that integrate multiple antiretroviral agents into a single tablet. The physical properties and purity of the synthetic compound are designed to ensure consistent absorption following oral ingestion, which is necessary for maintaining a consistent therapeutic presence in the body.

What is the General Purpose of an Integrase Inhibitor?

The primary purpose of this medication is to interrupt the HIV replication cycle to achieve and maintain suppression of the viral load within the bloodstream.

Dolutegravir works by targeting the HIV-1 integrase enzyme. By doing so, it prevents the virus from inserting its genetic material into the DNA of the host cell. The core function of this process is to prevent the virus from multiplying and spreading throughout the body. By blocking this viral DNA integration, the medication serves the fundamental goal of antiretroviral therapy: maintaining sustained control over the viral infection.

What side effects are possible with Tivicay?

Possible Side Effects and Safety Information

Tivicay (dolutegravir) is associated with both common and serious adverse reactions as documented in regulatory sources.

Common Adverse Reactions

Adverse drug reactions of moderate to severe intensity reported in clinical trials, with an incidence of ge 2%, primarily affect the Nervous System and Gastrointestinal systems. These include insomnia, headache, and fatigue. Other common events include nausea, diarrhea, and dizziness.

Serious Warnings and Precautions

1. Hypersensitivity Reactions: Potentially life-threatening, these reactions are characterized by rash, constitutional findings (such as fever and malaise), and sometimes organ dysfunction, including severe liver injury. The medication is contraindicated in patients with a history of a previous hypersensitivity reaction to dolutegravir. Immediate discontinuation is required if signs of a reaction develop.

2. Hepatotoxicity (Liver Injury): Hepatic adverse events, including transaminase elevations and acute liver failure, have been reported. Patients with underlying Hepatitis B or C co-infection may have an increased risk of worsening liver function, and monitoring for hepatotoxicity is recommended.

3. Embryo-Fetal Toxicity: Use of Tivicay at the time of conception and during the first trimester of pregnancy is associated with a risk of neural tube defects. An alternative treatment is considered during this critical period, and effective contraception is generally recommended for individuals of childbearing potential.

4. Immune Reconstitution Inflammatory Syndrome (IRIS): Patients with severe immune deficiency may develop an inflammatory response to existing or residual opportunistic pathogens shortly after starting combination antiretroviral therapy, which may require further medical evaluation.

5. Contraindications: Tivicay is contraindicated with the anti-arrhythmic medication dofetilide due to the risk of increased dofetilide plasma concentrations and serious events.

6. Drug Interactions: Tivicay should be taken separately from supplements containing cation-containing agents (e.g., antacids, iron, or calcium supplements) to prevent decreased dolutegravir concentration, which may lead to a loss of virologic response. However, when taken with food, Tivicay and iron or calcium supplements can be taken at the same time.

Overdose and Emergency Response

Overdose and When to Seek Help

Experience concerning Dolutegravir (Tivicay) overdosage is limited in regulatory documentation. Based on available clinical data, no specific symptoms or unique clinical signs have been identified to characterize an overdose event. High experimental exposure, including single doses significantly above therapeutic levels, has shown no evidence of dose-limiting toxicity. Reported manifestations associated with higher-than-normal dosing have been transient headache and gastrointestinal effects.

Mandated Emergency Actions and Management

In the event of a suspected or confirmed overexposure, official guidelines mandate that individuals seek immediate medical attention. This requires contacting a healthcare provider or local Poison Control Center right away, or proceeding to the nearest hospital emergency room.

There is no known specific antidote or specific treatment available for Dolutegravir overdose. Management is therefore symptomatic and supportive. The patient's clinical status should be monitored, with particular attention to assessing liver aminotransferases to manage any potential adverse reactions. Due to the active ingredient’s high binding to plasma proteins, its removal by dialysis is considered unlikely to be effective.

Therapeutic Uses of Tivicay

Tivicay is commonly used as part of a combination regimen for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection.

Sustained Control and Immune Support

Tivicay may be part of symptomatic management in therapy to achieve and maintain robust viral suppression in individuals with HIV-1 infection, supporting the effort to achieve and maintain an undetectable level. This application is relevant for easing the symptoms related to chronic viral activity. The medication's role is also to assist with the recovery of the patient's immune function, relevant in contexts marked by increased discomfort or tension by supporting the recovery of the body's defenses. By successfully managing the virus, Tivicay helps with managing the risk of associated illnesses, such as severe opportunistic infections and AIDS-defining conditions.

This medication is commonly used to help with conditions presenting with chronic viral activity and progressive immune decline. Indications include use in initial treatment scenarios, applied in clinical settings that involve acute or unstable symptom patterns, such as switching therapeutic support, and used when groups of symptoms appear suddenly or fluctuate, and supportive relief is needed.

“This application is relevant for addressing the constant, underlying viral replication, which supports the maintenance of general well-being and long-term health management.”

Quick Fact: Relief for Progressive Immune Deficiency

Eligibility and Restrictions for Use

Eligibility for Tivicay (Dolutegravir) Use

Official regulatory documents define strict population eligibility for Tivicay use based on medical history, age, organ function, and physiological state.

Classification	Population or Condition
Contraindicated (Must Not Use)	Patients with previous hypersensitivity reaction to dolutegravir
	Patients receiving dofetilide (antiarrhythmic drug)
Approved for Use	Adults with HIV-1 infection
	Pediatric patients aged at least 4 weeks and weighing at least 3 kg
Use Not Recommended	Patients with severe hepatic impairment (Child-Pugh grade C)
	Breastfeeding is not recommended due to potential for HIV-1 transmission
Conditional Use	Women at the time of conception through the first trimester of pregnancy (An alternative treatment should be considered)
	Infants younger than 4 weeks or weighing less than 3 kg (Safety/Efficacy not established)

Use is generally approved for adults and children meeting minimum age and weight thresholds. However, Tivicay is strictly contraindicated in patients with a history of severe allergy to the medicine or who are taking dofetilide. Use is not recommended for patients with severe liver impairment, and an alternative treatment should be considered for women during early pregnancy due to regulatory concerns regarding potential fetal risk.

What should I know about interactions with other medicines?

Tivicay (Dolutegravir) has formally documented interaction patterns that regulate its co-administration with other medicines and products. The regulatory profile classifies these interactions based on their potential impact on drug concentration and absorption.

A primary restriction is the contraindication of co-administering Dolutegravir with the antiarrhythmic medicine Dofetilide. This is due to Dolutegravir's inhibition of renal transporters, which significantly increases the plasma concentration of Dofetilide, posing a risk of serious events.

Dolutegravir's inhibition of these same transporters, including OCT2 and MATE1, is also documented to increase the exposure of the antidiabetic medicine Metformin, requiring monitoring or adjustment of the co-administered medicine's dose.

Conversely, some potent inducers of metabolic enzymes (UGT1A1/CYP3A4), such as Rifampin and certain antiretroviral agents, reduce the systemic concentration of Dolutegravir. Regulatory documents specify that co-administration with these enzyme inducers necessitates a mandated increase in the Tivicay dose.

Another category of restriction involves substances containing polyvalent cations, such as antacids, Sucralfate, and oral iron or calcium supplements. To prevent the significant reduction in Dolutegravir absorption caused by chelation, a strict timing rule applies: Tivicay must be administered 2 hours before or 6 hours after these products. An exception is noted for oral iron or calcium supplements, which can be taken simultaneously with Tivicay if co-administered with food.

Mechanism of Action

How Tivicay Works: Mechanism of Action

Targeting the HIV-1 Integrase Enzyme

The mechanism of action for Dolutegravir centers on selective inhibition of the HIV-1 integrase enzyme. This molecule acts within the CD4^+ T-cells by binding to the enzyme's active site, a structural domain crucial for its function. By occupying this site, the drug prevents the viral protein from performing its essential catalytic role in the HIV replication cycle.

Blocking Viral DNA Integration

Inhibition of the integrase enzyme directly and immediately interrupts the Proviral DNA formation pathway. This action specifically blocks the strand transfer step, preventing the HIV genetic material from being permanently inserted into the host cell's DNA. The physiological consequence of halting this step is the interruption of viral protein synthesis necessary for new virion formation.

Mechanism Leads to Systemic Control

The resulting mechanistic cascade—from enzyme blockade to integration prevention—creates a functional block on the production of new virus particles throughout the system. While this mechanism is robust, its functional boundary is defined by the virus's ability to mutate the integrase enzyme, which can reduce the drug's binding affinity and lead to a compromised inhibitory effect.

Dosage and Administration Information

How Tivicay is Used: Official Administration Guidelines

Tivicay (dolutegravir) is a medication taken as part of a long-term, continuous treatment regimen, with all instructions for use defined by official prescribing guidelines.

Dosage and Frequency

The approved route of administration for all formulations is oral.

Population	Standard Dosing Regimen	Maximum Recommended Dose	Note on Use
Adults (INSTI-naïve)	50 mg once daily	50 mg twice daily	Twice daily dosing is mandatory when co-administered with certain enzyme-inducing medicines or in cases of integrase inhibitor resistance.
Adults (INSTI-experienced)	50 mg twice daily	50 mg twice daily	The decision to use this dose depends on the patient's specific resistance profile.

Special Administration Instructions

With or Without Food:

Standard doses of the film-coated tablets can be taken with or without food.
However, if there is documented integrase class resistance, the dose should be taken preferably with food to enhance dolutegravir exposure.

Handling Missed Doses: If a dose is missed, the patient should take it as soon as possible, provided the next scheduled dose is not due within 4 hours. If the next dose is due within 4 hours, the missed dose should be skipped, and the regular schedule resumed.

Cation-Containing Agents: To maintain appropriate absorption, Tivicay must be taken 2 hours before or 6 hours after supplements containing polyvalent cations (e.g., calcium, iron, or aluminum-containing antacids). This time separation is not required if Tivicay and the supplements are taken simultaneously with food.

Pediatric Dosing and Formulations

Pediatric dosing, starting from four weeks of age and a minimum weight of 3 kg, is strictly weight-based. The available film-coated tablets and tablets for oral suspension (dispersible form) are not bioequivalent and must not be substituted for one another on a milligram-for-milligram basis. Patients changing formulations must follow the specific dosing tables for the new product. No dosage adjustment is required for adults with mild, moderate, or severe (non-dialysis) renal impairment.

Recent Clinical Evidence

Research establishing the primary evidence base for dolutegravir (Tivicay) was conducted in large Phase III Randomized Controlled Trials (RCTs) focusing on people starting HIV treatment for the first time. These studies compared dolutegravir-based regimens against other treatment standards, examining whether participants achieved viral suppression (HIV-1 RNA below 50 copies/mL) and tracking changes in CD4+ T-cell count, a marker of immune status. Trials reported data regarding the proportion of participants who reached viral suppression over the study period.

Research has also explored dolutegravir regimens in individuals who are virologically suppressed on their current therapy. These studies, often designed as non-inferiority trials, monitored the maintenance of viral suppression after switching to a new regimen. Findings indicate that virologic suppression was maintained in a proportion of individuals over several years of observation.

Research was also conducted on adults who have experienced virological failure on previous antiretroviral regimens. These trials examined the re-establishment of viral suppression when dolutegravir was combined with an Optimized Background Regimen (OBR). Findings describe patterns observed in these studies where viral control was measured, though virologic response rates in these complex settings may be lower than for people starting treatment for the first time.

Evidence was evaluated in specific age groups, including adolescents and children as young as four weeks old, using age- and weight-specific regimens developed for the studies. Trials monitored viral load changes and immune markers in these pediatric populations. Additionally, evidence was evaluated in older adults, often derived from subgroup analyses. However, there is limited information for long-term outcomes spanning many decades of use, and data for certain groups, such as pregnant individuals or those with severe organ dysfunction, remain insufficient. Research is ongoing to address these gaps.

Key Studies & References

Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV (NIH/HHS Panel)

Frequently Asked Questions (FAQ)

Common questions about Tivicay (FAQ)

Q: Is Tivicay an HIV medicine or something else?

A: Tivicay, which contains the active ingredient dolutegravir, is classified as an antiretroviral agent. Official documents describe it as a medication specifically indicated for the treatment of HIV-1 infection in both adults and eligible children.

Q: Can Tivicay be used by itself?

A: Tivicay is primarily indicated for use in combination with other antiretroviral agents as part of a complete treatment regimen for HIV-1 infection. In certain situations, it may be used in specific two-drug complete regimens for virologically suppressed adults who meet particular criteria, but it is generally not used as a single medication.

Q: Does Tivicay cure HIV?

A: Official regulatory patient information states that Tivicay, like other antiretroviral therapies, does not cure HIV infection. Its function is to reduce the amount of the virus in the body to a very low level and help maintain that control over time.

Q: Are there any long-term effects associated with using Tivicay for many years?

A: Long-term data spanning many decades of Tivicay use are currently limited. However, for patients on long-term combination antiretroviral therapy in general, regulatory documents note that cases of osteonecrosis (a condition related to bone tissue) have been reported. Regular monitoring is part of long-term care.

Q: Does Tivicay interact with over-the-counter pain relievers like ibuprofen?

A: Regulatory documents require informing your healthcare provider about all medicines you take, including both prescription and over-the-counter medicines, as they may interact with Tivicay. While the official label does not specifically name common pain relievers like ibuprofen, it is important that all concurrent medications are disclosed.

Q: Is Tivicay a pill that must be swallowed whole?

A: The film-coated tablets are generally instructed to be swallowed whole with water. A separate formulation, called Tivicay PD (dispersible tablets), is available for use in children and is designed to be mixed with water to create an oral suspension.

Q: Why do some people switch from older HIV medications to Tivicay?

A: Dolutegravir, the active ingredient in Tivicay, is described in medical guidelines as having a high genetic barrier to resistance. This desirable profile means it is often a preferred component in initial treatment plans and can be used when switching from older regimens for reasons related to efficacy or side effect profile.

Q: Can Tivicay be used to prevent HIV infection?

A: Tivicay is officially recommended by some national guidelines, in combination with other drugs, for Non-Occupational Post-Exposure Prophylaxis (PEP). However, regulatory documents indicate it is not indicated for Pre-Exposure Prophylaxis (PrEP).

Q: Does Tivicay cause weight changes for most people?

A: Weight changes are not universally listed as common adverse reactions in the main clinical trials. However, some studies and post-marketing data have reported weight gain in patients treated with dolutegravir-based regimens.

Q: Can a person with kidney problems use Tivicay?

A: Official dosing guidelines state that no dosage adjustment is generally required for people with mild, moderate, or severe (non-dialysis dependent) renal impairment. However, for INSTI-experienced patients with severe kidney problems, caution is described in the product information due to potential changes in drug concentration.

Q: What does official guidance say about using Tivicay in older adults?

A: There is limited clinical data for patients over 65 years of age. Regulatory guidance advises caution because older adults are more likely to have age-related conditions affecting the kidneys, liver, or heart, which may require careful management.

Q: Does Tivicay affect the ability to drive or operate machinery?

A: Regulatory documents advise patients that Tivicay may cause nervous system effects such as dizziness. Patients are advised that this effect may impair the ability to drive or safely operate complex machinery.

Q: Is there a generic version of Tivicay available?

A: Dolutegravir is subject to patent protections in many jurisdictions, which means a generic equivalent of the Tivicay brand tablet is currently not available in the United States and several other regulated markets. Generic versions of dolutegravir are available in certain lower-income countries.

Q: Can Tivicay interact with herbal remedies or supplements?

A: Yes, official patient information explicitly warns that Tivicay can interact with herbal supplements, such as St. John’s wort. These interactions could potentially affect the amount of Tivicay in the body and reduce its effectiveness.

Q: What is the risk of developing resistance to Tivicay over time?

A: Tivicay is known to have a high genetic barrier to resistance. While resistance can still develop, studies show that treatment failure on this drug is typically associated with a low rate of developing new resistance to it.

Q: What regulatory bodies have approved Tivicay?

A: Tivicay has been approved by numerous governmental drug agencies globally. The list includes the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and Health Canada, among others, ensuring its wide availability for treatment.

Q: How long does it typically take for Tivicay to start working in the body?

A: Clinical studies have demonstrated that Tivicay can lead to a rapid reduction in the viral load, with significant changes often measured within the first few days of starting therapy. The overall goal of achieving full viral suppression is typically measured over several weeks or months.

Q: What is the maximum amount of time Tivicay can be used?

A: Tivicay is indicated for the long-term, continuous treatment of HIV-1 infection. Official product documents do not define a maximum duration, as the medication is intended for lifelong use to maintain control over the viral infection.

Q: Do official documents mention specific mental health concerns with Tivicay?

A: Official documents list some psychiatric and nervous system side effects reported in clinical trials, including insomnia, dizziness, and abnormal dreams. The need for careful monitoring of patients with pre-existing mental health conditions is noted in guidance.

Q: Is it true that Tivicay is sometimes used for people who have failed other treatments?

A: Yes, regulatory documents describe a specific dosing regimen for INSTI-experienced adults, who are people who have experienced virologic failure on a previous integrase inhibitor-containing regimen. Its use in this group is based on a patient’s specific drug resistance profile.

Q: What are the expected benefits of Tivicay as described in patient information?

A: The expected benefits outlined in patient information are two-fold: to reduce the amount of HIV in the blood to a low level (viral suppression) and to increase the CD4 cell count, which helps strengthen the immune system's ability to fight infection.

Q: Does Tivicay require special monitoring or tests?

A: Yes, official guidance recommends that patients using Tivicay will need regular blood tests as part of their ongoing care. Specific monitoring of liver function is also recommended for patients who have co-infection with Hepatitis B or C.

Q: Does Tivicay affect the results of other blood tests?

A: Yes, Tivicay is known to cause a reversible increase in blood levels of serum creatinine by inhibiting a renal transport protein. Regulatory documents note that this change is usually not considered a sign of actual kidney damage, but it is a measured effect of the drug on that specific test result.

How should Tivicay be stored and disposed of?

Storage and Disposal of Tivicay (Dolutegravir)

The official storage conditions for Tivicay (dolutegravir) are set by regulatory bodies to maintain product quality.

Storage Requirements

Tivicay must be stored at controlled room temperature, specifically below 86 F (30 C). The tablets must be kept in their original container with the lid tightly closed to ensure protection from moisture. The desiccant packet inside the original bottle must not be removed. All medication must be kept out of the reach of children.

Disposal Instructions

Unused or expired Tivicay tablets must be disposed of according to local regulations. Consult a pharmacist or local environmental authorities for the proper procedures for pharmaceutical waste disposal.

Tivicay